Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Population Pharmacokinetics of Ofatumumab in Patients With Chronic Lymphocytic Leukemia, Follicular Lymphoma, and Rheumatoid Arthritis

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Pharmacokinetics of high-dose intravenous melatonin in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Herbert Struemper
  • Mark Sale
  • Bela R Patel
  • Mikkel Østergaard
  • Anders Osterborg
  • William G Wierda
  • Anton Hagenbeek
  • Bertrand Coiffier
  • Roxanne C Jewell
View graph of relations
Ofatumumab is a human monoclonal antibody directed at CD20 approved for treatment of chronic lymphocytic leukemia. The population pharmacokinetics of intravenous ofatumumab were characterized in patients with relapsed/refractory chronic lymphocytic leukemia, relapsed/refractory follicular lymphoma, and rheumatoid arthritis, diseases with widely varying CD20(+) B-cell counts in blood. Serum concentration data from a total of 477 patients who received ofatumumab doses ranging from 100 mg to 2000 mg in different dosing regimens were analyzed to determine the pharmacokinetic characteristics of ofatumumab across different patient groups and to identify factors contributing to the pharmacokinetic variability. Ofatumumab pharmacokinetics were well described by a linear two-compartment model component to represent non-specific monoclonal antibody clearance from the central compartment interacting with a model component representing the target-mediated clearance of ofatumumab by binding to CD20 expressed on B cells. The clearance (7.5 mL/h) and steady-state volume of distribution (5.3 L) for the linear, non-specific component were consistent with results obtained for other monoclonal antibodies. The target-mediated clearance component was related to the disease-specific number of circulating B cells, which will allow simulation of the contribution of target-mediated clearance to ofatumumab pharmacokinetics in untested disease states with data on B-cell counts and turnover.
Original languageEnglish
JournalJournal of Clinical Pharmacology
Pages (from-to)818-27
Number of pages10
Publication statusPublished - 20 Jan 2014

ID: 42708276